FINWIRES · TerminalLIVE
FINWIRES

$AZN

28 stories mentioning AZN

Every FINWIRES story that references AZN, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Wire

AstraZeneca Says FDA Approves Truqap Combination for PTEN-Deficient Prostate Cancer

AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer.The approval targets about 35,000 patients annually in the US, where roughly one in four carry PTEN-deficient tumours, the company said.AstraZeneca said the decision was based on a phase 3 trial, which showed the combination reduced the risk of radiographic disease progression or death by 19% and extended median progression-free survival to 33.2 months versus 25.7 months for standard treatment.The most common grade 3 or higher side effects, occurring in 67% of patients, included rash and elevated blood sugar levels, the company said.The FDA also approved a companion diagnostic test to identify eligible patients, while a regulatory review is ongoing in the European Union.Price: $179.61, Change: $-2.67, Percent Change: -1.46%

$AZN
Asia Markets

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.53% to 1,917.29 on the S&P Europe Select ADR Index, which is up more than 2% for the week so far.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which advanced 8.2% and 5.8% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and pharmaceutical company Ascendis Pharma (ASND), which increased 4.8% and 3.2% respectively.The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and medical device maker EDAP TMS (FOCL), which dropped 3.2% and 1.5% respectively. They were followed by software firm SAP (SAP) and semiconductor company Sequans Communications (SQNS), which lost 1.3% and 0.6% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which rose 3.7% and 3.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biotech firm Autolus Therapeutics (AUTL), which were up 2.7% and 1.9% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which fell 3.7% and 3.4% respectively. They were followed by medical device maker Smith & Nephew (SNN) and pharmaceutical company AstraZeneca (AZN), which were off 0.9% and 0.6% respectively.

$AKTX$ASND$AUTL$AZN$DAVA$DBVT$EVAX$FOCL$MREO$NOK$SAP$SLN$SNN$SQNS$TRIB$TRVG
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, AstraZeneca's (AZN) Alexion Rare Disease unit said Friday that a phase 3 program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. Its shares were down 0.2%.The Centers for Medicare & Medicaid Services will not impose intermediate sanctions on Elevance Health (ELV) at this time based on the health insurer's attestation to corrective action steps it has taken, the agency said Friday. CMS notified Elevance in February of its determination to impose intermediate sanctions for "substantial and persistent noncompliance with Medicare Advantage risk adjustment data submission requirements." Elevance shares rose 0.3%.Becton, Dickinson (BDX) said it has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing. The shares were down 0.9%.Replimune (REPL) shares surged 84% after the firm said Friday it will resubmit its biologics license application for vusolimogene oderparepvec for advanced melanoma in the coming days.

$AZN$BDX$ELV$REPL
Sectors

Sector Update: Healthcare Stocks Fall in Afternoon Trading

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, AstraZeneca's (AZN) Alexion Rare Disease unit said Friday that a phase 3 program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. Shares were fractionally lower.Becton, Dickinson (BDX) said it has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing. Shares were little changed.Replimune (REPL) shares surged 85% after the firm said Friday it will resubmit its biologics license application for vusolimogene oderparepvec for advanced melanoma in the coming days.

$AZN$BDX$REPL
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, AstraZeneca's (AZN) Alexion Rare Disease unit said Friday that a phase 3 clinical program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. AstraZeneca shares were up 0.4%.

$AZN
Wire

AstraZeneca Working With Nucs AI on Prostate Cancer Research

AstraZeneca (AZN) started a collaboration with Nucs AI to develop artificial intelligence-driven response prediction models for an oncology treatment, Nucs AI said Friday.The collaboration will focus on creating predictive tools for a prostate-specific membrane antigen-targeted radioconjugate used in metastatic prostate cancer cases, the company said.The company will modify and verify an imaging biomarker product to match upcoming radioconjugate therapies, Nucs AI said.Price: $185.24, Change: $-0.09, Percent Change: -0.05%

$AZN
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 4.3%.Agilent Technologies (A) stock jumped 18% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 5% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.2%.

$A$AZN$ILMN$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.3%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.1%.

$AZN
Wire

AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer

Astrazeneca's (AZN) durvalumab, in combination with Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday.Durvalumab's efficacy was evaluated in the Potomac study, a randomized, open-label, multi-center trial of 1,018 patients with high-risk NMIBC following transurethral resection of bladder tumor, according to the statement.A statistically significant improvement in disease-free survival was observed with durvalumab plus BCG induction and maintenance compared with BCG induction and maintenance alone.The recommended durvalumab dose for patients weighing at least 30 kilograms is 1,500 mg every four weeks for 13 cycles, in combination with BCG induction and maintenance treatment. Treatment should continue until disease recurrence, progression, unacceptable toxicity, or a maximum of 13 cycles.Price: $184.89, Change: $-0.77, Percent Change: -0.41%

$AZN
Asia Markets

Fresh Military Strikes Between US, Iran Drag US Equity Futures Pre-Bell

US equity futures were edging lower pre-bell Thursday as fresh US and Iranian strikes once again threatened the fragile ceasefire between the two nations, reducing optimism surrounding a potential peace deal.Dow Jones Industrial Average futures were 0.3% lower, S&P 500 futures were down 0.1%, and Nasdaq futures were 0.2% lower.The US military said it had fired on Iranian drones over the Strait of Hormuz and attacked a military site in the port city of Bandar Abbas, which is the second time in three days it has struck targets in Iran for what it called self-defense. Iran said it responded by launching an attack on an American air base in the region.Traders observed the latest round of earnings, including those of several major Canadian banks. Royal Bank of Canada (RY) reported higher fiscal Q2 adjusted earnings and revenue, while Toronto-Dominion Bank (TD) posted increased fiscal Q2 adjusted earnings amid lower revenue.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 2.2% at $94.26 per barrel and US West Texas Intermediate crude 2.4% higher at $90.73 per barrel.The April core personal consumption expenditures price index, the Federal Reserve's preferred inflation gauge, released at 8:30 am ET, gained 0.2%, lower than the 0.3% increase in the prior month and the expected 0.3% gain in a survey compiled by Bloomberg.Initial jobless claims rose to 215,000 in the week ended May 23 from 210,000 level in the previous week, compared with expectations for a smaller increase to 211,000. Preliminary Q1 GDP growth was recorded at a 1.6% rise, compared with the advance estimate of a 2% increase.Durable goods new orders rose 7.9% in April after a 1.3% gain in the prior month, compared with expectations for a 4% increase.In other world markets, Japan's Nikkei closed 0.5% lower, Hong Kong's Hang Seng ended 1.3% lower, and China's Shanghai Composite finished 0.1% higher. Meanwhile, the UK's FTSE 100 was down 1%, and Germany's DAX index was 0.7% lower in Europe's early afternoon session.In equities, Dell Technologies (DELL) shares were up 4.6% after the company said its unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative. Snowflake (SNOW) stock was 37% higher after the cloud-based data platform lifted its fiscal 2027 product revenue outlook and agreed to a $6 billion infrastructure spending deal with Amazon's (AMZN) Amazon Web Services. Royal Bank of Canada shares were up 1.7% after the bank reported its fiscal Q2 financial results.On the losing side, HSBC (HSBC) stock was down 2.2% after a Bloomberg News report that UK's Cambridge University was withdrawing its investments from institutions providing financial support to fossil fuels, including the British bank. AstraZeneca (AZN) shares were 0.8% lower after the company said that the US Food and Drug Administration delayed the decision deadline for its new drug application regarding a combination breast cancer treatment.

Dow JonesNasdaq CompositeS&P 500$AMZN$AZN$DELL$HSBC$RY$SNOW$TD
Wire

AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer

AstraZeneca (AZN) and Daiichi Sankyo said Friday that the US Food and Drug Administration has approved Datroway for first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.The approval followed the FDA's priority review based on phase 3 data showing Datroway, or datopotamab deruxtecan, improved median overall survival to 23.7 months compared with 18.7 months for patients treated with chemotherapy, the companies said.Datroway also reduced the risk of disease progression or death by 43%, with median progression-free survival of 10.8 months versus 5.6 months for chemotherapy, according to the companies.The safety profile of Datroway was evaluated in 319 patients, with serious adverse reactions including pneumonia, vomiting, COVID-19 and anemia reported in more than 1% of patients, while one fatality was linked to interstitial lung disease or pneumonitis, Daiichi Sankyo said.Datroway is a TROP2-directed antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca.Shares of AstraZeneca were down 1.4% in Friday trading.Price: $187.16, Change: $-2.59, Percent Change: -1.36%

$AZN
Research

Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We add shares of AstraZeneca Plc (AZN) to the Total Return portfolio, replacing Medtronic (MDT). In our view, AZN's pipeline, one of the strongest vs. peers, provides a compelling long-term growth story. Late-stage pipeline execution remains robust, with four positive high-value Phase 3 readouts and 14 regulatory approvals achieved so far in 2026. More than 20 Phase 3 trial readouts are expected in 2026, offering multiple near-term catalysts. We think the near-term patent expirations (Farxiga, April 2026, and Soliris, 2027) are well-managed through a robust pipeline and successful lifecycle management. In our view, the solid oncology segment remains a primary growth contributor. AZN has built a strong oncology portfolio, with key drugs like Enhertu, Tagrisso, and Imfinzi that are protected well into the 2030s. Q1 2026 demonstrated sustained momentum, with the oncology segment leading revenue growth (+16% CER, with Enhertu +34% CER based on continued global demand).

$AZN
Wire

Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning trading Monday, as Wall Street monitored oil prices and US Treasury yields amid the ongoing conflict in the Middle East.In company news, NextEra Energy (NEE) and Dominion Energy (D) said Monday they have entered into a definitive agreement to combine in an all-stock deal. Under the terms of the transaction, Dominion shareholders will receive a fixed exchange ratio of 0.8138 shares of NextEra for each Dominion share they own at the close of the deal, which is expected in the next 12 to 18 months. NextEra shareholders will own about 74.5% of the combined company, while Dominion shareholders will own the remaining 25.5%. NextEra shares were down 5.5% around midday, while Dominion shares were up 9.6%.The US Supreme Court on Monday denied writ of certiorari petitions by six big pharmaceutical companies seeking to challenge the legality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol-Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court. Shares of AstraZeneca, Novartis, Johnson & Johnson and Bristol-Myers were up 1.1%, 0.8%, 0.4% and 0.5%, respectively, while Novo Nordisk was down 1%.Berkshire Hathaway (BRK.A, BRK.B) disclosed Friday in a regulatory filing that it sold all of its stake in UnitedHealth Group (UNH). Separately, a New York state court judge on Monday prohibited prosecutors from using some evidence found in the backpack of Luigi Mangione, who is standing trial for the murder of UnitedHealth Group's UnitedHealthcare CEO Brian Thompson, CNBC reported. UnitedHealth shares were down 1.5%, while Berkshire's class A and class B shares were up 0.2% and 0.1%, respectively.Citigroup (C) and BlackRock's (BLK) HPS Investment Partners are launching a 15 billion euro ($17.48 billion) private capital program to expand access to private financing for corporate and sponsor-owned borrowers in the Europe, the Middle East and Africa region, the companies said Monday. Citigroup shares were down 0.2%, while BlackRock shares were up 0.5%.Price: $88.24, Change: $-5.13, Percent Change: -5.49%

$AZN$BLK$BMY$BRK.A$BRK.B$C$D$JNJ$NEE$NVO$NVS$UNH
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from.Price: $183.25, Change: $+1.67, Percent Change: +0.92%

$AZN$BMY$JNJ$NVO$NVS
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

$AZN$BMY$JNJ$NVO$NVS
Asia Markets

European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading

European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.43% to 1,852.92 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and 3D printer company Materialise (MTLS), which climbed 11.4% and 10.4% respectively. They were followed by lender ING Group (ING) and biopharmaceutical company Cellectis (CLLS), which increased 2.3% and 2.1% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and internet browser company Opera (OPRA), which fell 1.7% and 1.6% respectively. They were followed by oil and gas company Eni (E) and lender Banco Santander (SAN), which were off 1.3% and 0.5% respectively.The gainers from the UK were led by biopharmaceutical companies NuCana (NCNA) and Akari Therapeutics (AKTX), which advanced 9.6% and 3.2% respectively. They were followed by communications company WPP (WPP) and lender Barclays (BCS), which were up 2.8% and 2.4% respectively.The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and mining company BHP Group (BHP), which dropped 9.9% and 2.1% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and pharmaceutical company AstraZeneca (AZN), which were down 1.3% each.

$AKTX$AMRN$AUTL$AZN$BCS$BHP$CLLS$E$ING$MTLS$NCNA$NVO$OPRA$SAN$SQNS$WPP
Wire

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN
Wire

AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports

AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports

$AZN
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.3% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.7%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.1%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged 38%.

$ABBV$AZN$BSX$KALV

Showing 1-20 of 28